Results 181 to 190 of about 25,426 (206)

NAD⁺‒circadian rhythm coupling in dementia. [PDF]

Alzheimers Dement
Zhang SQ, Lee J, Pan JP, Enger R, Hrubos-Strøm H, Musiek ES, Fang EF, Le W.   +7 more
europepmc   +1 more source

Cancer metabolism in radiation sensitization - complementary roles of O-GlcNAc transferase and PARP1. [PDF]

J Cell Sci
Efimova E, Liu Y, Averbek S, Choi S, Ha S, Ricco N, Lomeli I, Viguls E, Kim WY, Kron SJ.   +9 more
europepmc   +1 more source

TMPRSS2:ERG-directed radiosensitization: exploiting DNA repair rewiring in gene fusion-positive prostate cancer. [PDF]

J Clin Invest
Wang X, Chinnaiyan AM.
europepmc   +1 more source

Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation. [PDF]

PeerJ
Fan J, Song Y.
europepmc   +1 more source

STING-ERO1 signaling exacerbates PARylation-mediated parthanatos in sepsis. [PDF]

Cell Commun Signal
Li X, Zhou Q, Zhang X, Li Y, Yang Y, Wu J, Liu Q, Liu P, Jiang H, Liu J, Deng L, Lin Z, Wu C, Wu L, Zhao Y, Ren J, Wu X.   +16 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC

Cancer Letters, 2022
Hepatocellular carcinoma (HCC), a heterogeneous cancer with high mortality, is resistant to single targeted therapy; thus, combination therapy based on synthetic lethality is a promising therapeutic strategy for HCC. Poly (adenosine diphosphate [ADP]-ribose) polymerase 1 (PARP1) is the most recognized target for synthetic lethality; however, the ...
Caiyu Sun, Weiqiang Jing, Dapeng Ma
exaly   +3 more sources

Increased PARP1‐DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1‐DNA trapping is correlated with PARP1 inhibitor's cytotoxicity [PDF]

International Journal of Cancer, 2019
PARP1 inhibitors (PARPis) are used clinically during cancer therapy and are thought to exert their cytotoxicity through PARP1 polymerase inhibition and PARP1‐DNA trapping. Here, we showed no significant correlation between PARP1‐DNA trapping and cytotoxicity induced by PARPis.
Hua-Dong Chen, Yu-Ting Wang, Ne Guo
exaly   +4 more sources

Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation [PDF]

Nature Chemical Biology, 2019
PARP1 inhibitors (PARPi) are known to kill tumor cells via two mechanisms (PARP1 catalytic inhibition and PARP1 trapping). The relative contribution of these two pathways in mediating the cytotoxicity of PARPi, however, is not well understood. Here we designed a series of small molecule PARP degraders.
Shuai Wang, Lei Han, Jungsoo Han
exaly   +3 more sources

Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition

Cancer Letters, 2012
Although pre-clinical and clinical studies on PARP1 inhibitors, alone and in combination with DNA-damaging agents, show promising results, further ways to improve and broaden the scope of application of this therapeutic approach are warranted.
Siker Kimbung, Ida Johansson, Sofia K Gruvberger-Saal   +2 more
exaly   +2 more sources

PARG inhibition induces nuclear aggregation of PARylated PARP1

Structure
Poly (ADP-ribose) glycohydrolase (PARG) inhibitors are currently under clinical development for the treatment of DNA repair-deficient cancers; however, their precise mechanism of action is still unclear. Here, we report that PARG inhibition leads to excessive PARylated poly (ADP-ribose) polymerase 1 (PARP1) reducing the ability of PARP1 to properly ...
Katelyn J Noronha, Matthew A Murray, Ranjini K Sundaram   +2 more
exaly   +3 more sources